January 27, 2026

Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis: Exploring a 45% Upside Potential

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a key player in the biotechnology industry, holds a promising position in the healthcare sector with its focus on developing treatments for rare diseases. With..

Perrigo Company plc (PRGO): Investor Outlook Reveals a Potential 45.83% Upside

Perrigo Company plc (NYSE: PRGO), a key player in the healthcare sector, is making waves with a potential upside of 45.83% as suggested by its average target price. Headquartered in..

Zai Lab Limited (ZLAB) Stock Analysis: Eyeing a 169% Potential Upside in the Biotech Arena

Zai Lab Limited (NASDAQ: ZLAB) has emerged as a significant player in the biotech sector, with a focus on pioneering therapies in oncology, immunology, neuroscience, and infectious diseases. Based in..

Merus N.V. (MRUS) Stock Analysis: Exploring the Potential 7.78% Upside in the Biotech Sector

Merus N.V. (MRUS), a prominent player in the biotechnology sector, operates from the Netherlands with a keen focus on developing innovative antibody therapeutics. Although Merus is currently a clinical-stage company,..

Privia Health Group, Inc. (PRVA) Stock Analysis: A Healthcare Innovator with 29.67% Upside Potential

Privia Health Group, Inc. (NASDAQ: PRVA) is generating buzz in the healthcare sector as a promising player in the health information services industry. Based in Arlington, Virginia, Privia Health is..

Concentra Group Holdings Parent (CON) Stock Analysis: A Healthcare Play with a 28% Upside Potential

Investors with a keen eye on the healthcare sector may find Concentra Group Holdings Parent (NASDAQ: CON) an intriguing opportunity. With its robust presence in the medical care facilities industry,..

Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: A 31% Potential Upside in Neurological Innovations

Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a pioneering force in the biotechnology sector, is drawing considerable attention from investors due to its focused efforts on developing treatments for neurological and psychiatric..

CRISPR Therapeutics AG (CRSP) Stock Analysis: Unpacking the 52.71% Potential Upside for Investors

CRISPR Therapeutics AG (NASDAQ: CRSP), a leader in the biotechnology sector, is making headlines with its promising gene-editing technologies. With an impressive market cap of $5.21 billion, this Swiss-based company..

Haemonetics Corporation (HAE) Stock Analysis: Exploring a 34.56% Upside Potential in the Medical Devices Sector

Haemonetics Corporation (NYSE: HAE), a Boston-based innovator in medical technology, is capturing the attention of investors with its robust portfolio of healthcare solutions. The company’s strategic focus on automated plasma..

Metsera, Inc. (MTSR) Stock Analysis: Navigating the Uncharted Waters of a Clinical-Stage Biotech

Investors intrigued by the high-risk, high-reward nature of biotechnology stocks may find Metsera, Inc. (MTSR) an interesting case study. As a clinical-stage biotech company operating under the umbrella of Pfizer..

QuidelOrtho Corporation (QDEL) Investor Outlook: Analyzing a Potential 33.66% Upside in the Healthcare Sector

QuidelOrtho Corporation (NASDAQ: QDEL) is a prominent player in the healthcare sector, specializing in medical devices, particularly diagnostic testing solutions. With a market capitalization of $1.95 billion, this U.S.-based company..

Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis: Exploring a 56.89% Upside Potential

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stands out in the biotechnology sector with a market capitalization of $2.78 billion. As a player in the healthcare industry, Apellis is focused on addressing..

Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: Unveiling a Potential 60.89% Upside with Innovative Endocrine Solutions

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), headquartered in San Diego, California, stands as a beacon in the biotechnology sector, focusing on novel therapeutics for rare endocrine diseases and related tumors. With..

Immunovant, Inc. (IMVT) Stock Analysis: Exploring a 51.55% Upside Potential in the Biotech Sector

Immunovant, Inc. (IMVT), a prominent player in the biotechnology sector, has captured the attention of investors with its clinical-stage developments targeting autoimmune diseases. The New York-based company focuses on innovative..

Time Finance adds strategic hire to support £300m lending target

Strategic hire strengthens Time Finance’s intermediary reach as part of long-term lending growth plan...

Scholar Rock Holding Corporation (SRRK) Stock Analysis: Biotechnology Innovator with 12% Upside Potential

Scholar Rock Holding Corporation (NASDAQ: SRRK) stands out in the biotechnology sector with its innovative approach to treating serious diseases through targeted protein growth factor therapies. The Massachusetts-based company has..

PROCEPT BioRobotics (PRCT): A Robotics Innovator with a 71% Potential Upside

For investors with a keen eye on the healthcare sector, PROCEPT BioRobotics Corporation (NASDAQ: PRCT) presents an intriguing prospect. Specializing in medical devices, this San Jose-based company is at the..

Viking Therapeutics (VKTX): Analyst Ratings Indicate a Potential Upside of Over 194%

Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, is garnering significant attention from investors with its promising drug pipeline and substantial potential upside. With a market capitalization of $3.59..

Arcellx, Inc. (ACLX) Stock Analysis: Unpacking a 63.90% Potential Upside in the Biotech Sector

Arcellx, Inc. (NASDAQ: ACLX), a promising player in the biotechnology sector, has caught the attention of investors with its robust pipeline of immunotherapies targeting cancer and other incurable diseases. As..

PTC Therapeutics, Inc. (PTCT) Stock Analysis: Potential Upside with Innovative Rare Disorder Treatments

PTC Therapeutics, Inc. (PTCT) stands out in the biotechnology sector with its focus on developing and commercializing treatments for rare disorders. Headquartered in Warren, New Jersey, PTC Therapeutics is making..

Search

Funds

January 27, 2026

Time Finance adds strategic hire to support £300m lending target

Strategic hire strengthens Time Finance’s intermediary reach as part of long-term lending growth plan...
Search

Funds

January 27, 2026

FTSE 100

Funds